Relmada Therapeutics (RLMD) Common Equity (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Common Equity data on file, last reported at $218.7 million in Q1 2026.

• On a quarterly basis, Common Equity rose 874.72% year-over-year to $218.7 million in Q1 2026; TTM through Mar 2026 was $218.7 million, a 874.72% increase from a year earlier, with the FY2025 full-year figure at $86.5 million, up 143.55% from the prior year.
• Common Equity for Q1 2026 stood at $218.7 million, up from $86.5 million in the prior quarter.
• Over the last five years, Common Equity for RLMD reached as high as $218.7 million in Q1 2026 and fell as low as $9.5 million in Q3 2025.
• Historically, Common Equity has averaged $100.4 million across 5 years, with a median of $86.5 million in 2025.
• Across the five-year window, Common Equity sank 80.12% in 2025 and jumped 874.72% in 2026, its largest moves.
• Year by year, Common Equity stood at $140.4 million in 2022, then plunged by 39.22% to $85.4 million in 2023, then plunged by 58.38% to $35.5 million in 2024, then jumped by 143.55% to $86.5 million in 2025, then soared by 152.83% to $218.7 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $218.7 million in Q1 2026, $86.5 million in Q4 2025, and $9.5 million in Q3 2025.